Preventing Crohn's Disease recurrence after resection with adalimumab: Role of drug and anti-drug antibody levels

被引：0

作者：

Wright, E. ^{[1
,2
]}

Kamm, M. ^{[1
,2
,3
]}

Selvaraj, F. ^{[4
]}

Princen, F. ^{[4
]}

De Cruz, P. ^{[1
,2
]}

Hamilton, A. ^{[1
,2
]}

Ritchie, K. ^{[1
,2
]}

Krejany, E. ^{[1
,2
]}

Gorelik, A. ^{[1
,2
]}

Liew, D. ^{[1
,2
]}

Prideaux, L. ^{[1
,2
]}

Lawrance, I. ^{[1
,2
]}

Andrews, J. ^{[1
,2
]}

Bampton, P. ^{[1
,2
]}

Jakobovits, S. ^{[1
,2
]}

Florin, T. ^{[1
,2
]}

Gibson, P. ^{[1
,2
]}

Debinski, H. ^{[1
,2
]}

Gearry, R. ^{[1
,2
]}

Macrae, F. ^{[1
,2
]}

Samuel, D. ^{[1
,2
]}

Kronborg, I. ^{[1
,2
]}

Radford-Smith, G. ^{[1
,2
]}

Selby, W. ^{[1
,2
]}

Johnston, M. ^{[1
,2
]}

Woods, R. ^{[1
,2
]}

Elliott, P. R. ^{[1
,2
]}

Bell, S. ^{[1
,2
]}

Brown, S. ^{[1
,2
]}

Connell, W. ^{[1
,2
]}

Desmond, P. ^{[1
,2
]}

Singh, S. ^{[4
]}

机构：

[1] St Vincents Hosp, Melbourne, Vic, Australia

[2] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia

[3] Univ London Imperial Coll Sci Technol & Med, Med, London, England

[4] Prometheus Labs, Dept Res & Dev, San Diego, CA USA

来源：

JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P585

引用

页码：S373 / S373

页数：1

共 50 条

[31] Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Jyssum, Ingrid
Gehin, Johanna E.
Sexton, Joseph
Kristianslund, Eirik Klami
Hu, Yi
Warren, David John
Kvien, Tore K.
Haavardsholm, Espen A.
Syversen, Silje Watterdal
Bolstad, Nils
Goll, Guro Lovik
RHEUMATOLOGY, 2024, 63 (06) : 1746 - 1755
[32] Anti-Tumor Necrosis Factor Drug Levels and Anti-Bodies Are Associated With Crohn's Disease Recurrence At the Level of the Ileo-Colonic Anastomosis After Ileal Resection
Yarur, Andres
Trivella, Juan P.
Sussman, Daniel A.
Drake, Katherine
Barkin, Jamie S.
Hauenstein, Scott
Deshpande, Amar R.
Quintero, Maria A.
Singh, Sharat
Abreu, Maria T.
GASTROENTEROLOGY, 2014, 146 (05) : S243 - S244
[33] Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors
Ward, M. G.
Warner, B.
Unsworth, N.
Chuah, S. -W.
Brownclarke, C.
Shieh, S.
Parkes, M.
Sanderson, J. D.
Arkir, Z.
Reynolds, J.
Gibson, P. R.
Irving, P. M.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (02) : 150 - 161
[34] RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB
Kaur, P.
Chow, V.
Zhang, N.
Markus, R.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 714 - 714
[35] POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE
Nice, Rachel
Chanchlani, Neil
Kennedy, Nicholas A.
Green, Harry D.
Lin, Simeng
Gordon, Claire
Chee, Desmond
Hamilton, Benjamin
Bewshea, Claire
Goodhand, James
Ahmad, Tariq
McDonald, Timothy
Perry, Mandy
GUT, 2021, 70 : A103 - A103
[36] UTILITY OF MEASUREMENT ANTI TNF DRUG AND ANTI DRUG ANTIBODY LEVELS IN A COHORT OF PATIENTS WITH CROHN'S DISEASE: HOW DOES IT AFFECT CLINICAL PRACTICE?
Laird, S.
Caulfield, L.
Smith, L. A.
Winter, J. W.
Gaya, D. R.
Morris, A. J.
GUT, 2016, 65 : A151 - A152
[37] Intrapatient variability in adalimumab drug levels within and across cycles in patients with Crohn's disease
Ward, M.
Beswick, L.
Thwaites, P.
Hogg, J.
Rosella, G.
Reynolds, J.
Van Langenberg, D.
Gibson, P.
Sparrow, M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 143 - 144
[38] Higher Adalimumab Drug Levels Are Associated With Clinical and Endoscopic Remission in Patients With Crohn's Disease
Zittan, Eran
Kabakchiev, Boyko
Stempak, Joanne M.
Nguyen, Geoffrey C.
Croitoru, Kenneth
Van Assche, Gert A.
Steinhart, A. Hillary
Silverberg, Mark S.
GASTROENTEROLOGY, 2015, 148 (04) : S852 - S852
[39] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
Neasa Mc Gettigan
Aman Shah Afridi
Grace Harkin
Caroline Lardner
Stephen Patchett
Danny Cheriyan
Gavin Harewood
Karen Boland
Aoibhlinn O’Toole
International Journal of Colorectal Disease, 2021, 36 : 1231 - 1241
[40] The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
Mc Gettigan, Neasa
Afridi, Aman Shah
Harkin, Grace
Lardner, Caroline
Patchett, Stephen
Cheriyan, Danny
Harewood, Gavin
Boland, Karen
O'Toole, Aoibhlinn
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (06) : 1231 - 1241

← 1 2 3 4 5 →